Cancer Research
Treatment Study for Patients with Glioblastoma
Testing the use of the immunotherapy drugs ipilimumab and nivolumab plus radiation therapy compared to the usual treatment (temozolomide and radiation therapy) for newly diagnosed MGMT unmethylated Glioblastoma
AGE: ≥ 18 years old
GENDER: All
GENDER: All
TYPE: Interventional Study
CONDITION: Glioblastoma
HEALTHY PARTICIPANTS: No
CONDITION: Glioblastoma
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center or Virtual
Learn More About This Research Study
Please call 1-800-641-2422 for more information or complete the online form below.
Study Purpose
The purpose of this study is to compare the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma.
Who Can Participate
Participants 18 years of age and older who are diagnosed with may be eligible for this study.
Principal Investigator: Bryan Bonder, MD
